Research map: Risk of Neurological Adverse Events Between PD-L1 and PD-1 Inhibitors in South Korean Patients with Lung Cancer: A Target Trial Emulation Framework

Back to the article

Papers in this map

  1. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies · Erik B von Elm · 2007 · 22379 citations · Cited by this paper
  2. PD-L1 vs PD-1 inhibitors: comparing risks of neurological adverse events in patients with lung cancer · 2026 · Cites this paper
  3. Effectiveness and Tolerability of Vortioxetine in Major Depressive Disorder: A Real-World Study in Switzerland · 2026 · Related
  4. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship · Julian R. Molina · 2008 · 2895 citations · Cited by this paper
  5. Clinical Benefit of Multiple Myeloma Drugs at Regulatory Approval in Brazil, Europe, and the USA: A Retrospective Cohort Study (2003–2024) · 2026 · Related
  6. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update · Bryan J. Schneider · 2021 · 2223 citations · Cited by this paper
  7. Desvenlafaxine as a Potential First-Line Treatment for Major Depressive Disorder: A Comprehensive Review and Consensus-Based Clinical Perspective on Efficacy, Safety and Patient Selection Profiles · 2026 · Related
  8. Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data · Jee-Ae Kim · 2017 · 734 citations · Cited by this paper
  9. Determinants and Prognostic Impact of In-Hospital Sodium-Glucose Cotransporter-2 Inhibitor Initiation in Patients with Heart Failure · 2026 · Related
  10. The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application · Jennifer Leigh Lund · 2015 · 728 citations · Cited by this paper
  11. Missed Opportunities in the Therapeutic Patterns of Chronic Obstructive Pulmonary Disease: A Real-World Italian Study on the Impact of Severe Exacerbation on Mortality and Hospital Re-admission · 2026 · Related
  12. The importance of exosomal PDL1 in tumour immune evasion · Dhouha Daassi · 2020 · 636 citations · Cited by this paper
  13. Milsaperidone: First Approval · 2026 · Related
  14. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways · Yunlong Zhao · 2019 · 411 citations · Cited by this paper
  15. Cost-Consequences Analysis of Biologic Treatments for Moderate-to-Severe Crohn’s Disease Using Real-World Transition Probability and Cost Data in Thailand · 2026 · Related
  16. Competing risks analyses: objectives and approaches · Marcel Wolbers · 2014 · 339 citations · Cited by this paper
  17. Amyloid-Related Imaging Abnormalities in Anti-amyloid Therapy: Clinical Implications of Kinetics for Safer Use and Risk Stratification · 2026 · Related
  18. Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature · Rathi Narayana Pillai · 2017 · 333 citations · Cited by this paper
  19. Over-the-Counter Product Use Among Individuals with Vitiligo: A Cross-Sectional International Survey · 2026 · Related
  20. Graphical Depiction of Longitudinal Study Designs in Health Care Databases · Sebastian Schneeweiß · 2019 · 278 citations · Cited by this paper
  21. Safety, Tolerability, and Pharmacokinetics of Subcutaneous Extended-Release Injectable Olanzapine in Patients with Schizophrenia and Schizoaffective Disorder · 2026 · Related
  22. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors · Amanda C. Guidon · 2021 · 230 citations · Cited by this paper
  23. Programmed Death-1 (PD-1):PD-Ligand 1 Interactions Inhibit TCR-Mediated Positive Selection of Thymocytes · Mary E Keir · 2005 · 151 citations · Cited by this paper
  24. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database · Takahisa Mikami · 2021 · 110 citations · Cited by this paper
  25. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database · Kenichiro Sato · 2019 · 97 citations · Cited by this paper
  26. Immune checkpoint blockade for non–small cell lung cancer: What is the role in the special populations? · Raffaele Califano · 2019 · 45 citations · Cited by this paper
  27. Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo · Maohua Li · 2021 · 43 citations · Cited by this paper
  28. Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice · Macarena Villagrán‐García · 2022 · 42 citations · Cited by this paper
  29. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity · Yuankun Zhang · 2023 · 38 citations · Cited by this paper
  30. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years · Rosanna Ruggiero · 2023 · 28 citations · Cited by this paper
  31. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer · Chengdi Wang · 2021 · 27 citations · Cited by this paper
  32. Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development · Ke Cheng · 2021 · 15 citations · Cited by this paper
  33. Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors · Yanting Zhou · 2023 · 14 citations · Cited by this paper
  34. Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study · Yong Joon Kim · 2024 · 13 citations · Cited by this paper
  35. Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors · Yu Hua Chen · 2024 · 10 citations · Cited by this paper
  36. Determinants of immune checkpoint inhibitor use and factors linked to neurological adverse events in Korean lung cancer · Sang Hee Kim · 2024 · 1 citation · Cited by this paper
  37. Untitled · Cited by this paper
  38. Untitled · Cited by this paper
  39. Untitled · Cited by this paper

Source: OpenAlex (CC0)